PANTAX studies Scandion Oncology´s lead compound SCO-101 as a combination treatment in pancreatic cancer. The outcome of the trial will be presented at
The poster presents data analysis from the PANTAX phase Ib trial, studying Scandion’s lead compound SCO-101 in combination with standard of care chemotherapies gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Topline results were announced in
The data confirms that SCO-101 is safe and well-tolerated in this indication and combination, thereby also supporting the general profile of SCO-101 as well-tolerated in combination with different chemotherapies in patients with late-stage disease.
In the trial, dose limiting toxicity were observed in two patients in the cohort treated with 250 milligram of SCO-101, hence the maximum tolerated dose for SCO-101 concurrent with gemcitabine and nab-paclitaxel was determined to be 200 milligram once daily for 6 days on a bi-weekly schedule.
Data from the PK profile demonstrated that a 6-day schedule of SCO-101 resulted in SCO-101 accumulation and drug-exposure proportional to dose.
“We are excited to have the data from our successful dose finding in PANTAX communicated at the
The poster abstract (titled “ABCG transporter and SRPK1 kinase inhibition of chemotherapy resistance: A phase Ib clinical trial of safety and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer”) can be found at the congress website: https://www.esmo.org/meeting-calendar/esmo-congress-2023/abstracts
Scandion expects to present a final analysis of all safety and efficacy outcomes from PANTAX in the first half of 2024.
For further information please contact:
Johnny Stilou, CFO
Phone: +45 2960 3532
E-mail: jos@scandiononcology.com
The information was provided by the contact person above for publication on
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.
Scandion is based in
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.
© Modular Finance, source